CYTK

Cytokinetics, Incorporated

Price Chart

Latest Quote

$82.62

+0.69 (+0.84%)

Current Price

Previous Close	$81.93
Open	$81.03
Day High	$82.76
Day Low	$80.33
Volume	1,180,341

Fetched: 2026-07-16T04:03:44

Stock Information

Shares Outstanding	135.77M
Total Debt	$1.44B
Cash Equivalents	$818.55M
Revenue	$105.81M
Net Income	$-829.61M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$10.89B
EPS (TTM)	$-6.83
Exchange	NMS

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$10.60B
Sales	$105.81M
Income	$-829.61M
Book/sh	$-6.65
Cash/sh	$6.03
Employees	673

Financial Ratios

Quick Ratio	4.14
Current Ratio	4.21

Returns & Margins

ROA	-31.54%
Gross Margin	-290.73%
Operating Margin	-948.69%

Ownership

Insider Ownership	0.67%
Institutional Ownership	118.81%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-17.11
P/S	102.88
P/B	-12.05

Analyst Data

Recommendation	strong_buy
Target Price	$107.80

Technical Indicators

SMA20	$83.03
SMA50	$77.74
SMA200	$66.85
RSI	44.57
ATR	3.1671

Shares Float	123.87M
Short Float	20.01%
Short Ratio	7.16
Volatility	0.42
Rel Volume	0.65

Performance History

Week	-5.53%
Month	+6.61%
Quarter	+22.56%
6 Months	+24.12%
YTD	+29.89%
Year	+107.29%
3 Years	+127.20%
5 Years	+309.29%
10 Years	+721.52%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-07-17	$80.18	1,588,500
2026-07-16	$80.36	1,406,800
2026-07-15	$82.62	1,334,100
2026-07-14	$81.93	1,439,500
2026-07-13	$82.24	1,891,500
2026-07-10	$84.87	1,768,000
2026-07-09	$86.07	1,691,600
2026-07-08	$84.88	2,377,500
2026-07-07	$85.56	2,293,400
2026-07-06	$85.57	2,239,500
2026-07-02	$86.49	2,030,200
2026-07-01	$85.26	2,147,100
2026-06-30	$85.19	2,403,800
2026-06-29	$87.26	3,635,300
2026-06-26	$82.19	7,164,200
2026-06-25	$80.80	2,386,600
2026-06-24	$81.20	2,425,700
2026-06-23	$80.01	2,077,600
2026-06-22	$79.17	2,888,200
2026-06-18	$78.78	3,547,500

About Cytokinetics, Incorporated

Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.

📰 Latest News

All You Need to Know About Cytokinetics (CYTK) Rating Upgrade to Buy

Zacks • 2026-07-15T16:00:05Z

Wall Street Analysts Think Cytokinetics (CYTK) Could Surge 30.54%: Read This Before Placing a Bet

Zacks • 2026-07-15T13:55:02Z

What This Cytokinetics Insider Sale Might Mean With the Stock Up 110%

Motley Fool • 2026-07-14T21:40:21Z

Is Cytokinetics (CYTK) A Bargain On Myqorzo Approval Or Already Fully Priced?

Simply Wall St. • 2026-07-11T06:13:24Z

How Myqorzo’s Commercial Launch At Cytokinetics (CYTK) Has Changed Its Investment Story

Simply Wall St. • 2026-07-11T01:12:05Z

Will Myqorzo Drive Cytokinetics Higher Despite Competitive Pressure?

Zacks • 2026-07-10T18:10:00Z

Is Cytokinetics, Incorporated (CYTK) A Good Stock To Buy Now?

Insider Monkey • 2026-06-29T17:30:25Z

Cytokinetics Seen Gaining From Myqorzo Momentum to Treat Heart Conditions, UBS Says

MT Newswires • 2026-06-29T16:35:42Z

Adobe downgraded, Roblox upgraded: Wall Street's top analyst calls

The Fly • 2026-06-29T13:44:00Z

Entertainment Stocks Madison Square Garden, Sphere Rally To New Highs

Investor's Business Daily • 2026-06-26T18:40:22Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Reconciled Cost Of Revenue	$416,026,000	$339,408,000	$330,123,000	$240,813,000
Cost Of Revenue	$416,026,000	$339,408,000	$330,123,000	$240,813,000
Total Revenue	$88,039,000	$18,474,000	$7,530,000	$94,588,000
Operating Revenue	$88,039,000	$18,474,000	$7,530,000	$94,588,000
Expenses
Interest Expense	$103,868,000	$86,512,000	$57,668,000	$51,156,000
Total Expenses	$700,297,000	$554,722,000	$503,735,000	$418,790,000
Other Income Expense	$-117,249,000	$-18,300,000	-	$-24,939,000
Other Non Operating Income Expenses	$-200,000	$-19,600,000	-	-
Net Non Operating Interest Income Expense	$-55,448,000	$-34,978,000	$-30,039,000	$-39,814,000
Interest Expense Non Operating	$103,868,000	$86,512,000	$57,668,000	$51,156,000
Operating Expense	$700,297,000	$554,722,000	$503,735,000	$418,790,000
General And Administrative Expense	$284,271,000	$215,314,000	$173,612,000	$177,977,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-784,955,000	$-589,526,000	$-526,244,000	$-388,955,000
Net Interest Income	$-55,448,000	$-34,978,000	$-30,039,000	$-39,814,000
Interest Income	$48,420,000	$51,534,000	$27,629,000	$11,342,000
Normalized Income	$-667,906,000	$-590,826,000	$-526,244,000	$-364,016,000
Net Income From Continuing And Discontinued Operation	$-784,955,000	$-589,526,000	$-526,244,000	$-388,955,000
Total Operating Income As Reported	$-612,258,000	$-536,248,000	$-496,205,000	$-324,202,000
Net Income Common Stockholders	$-784,955,000	$-589,526,000	$-526,244,000	$-388,955,000
Net Income	$-784,955,000	$-589,526,000	$-526,244,000	$-388,955,000
Net Income Including Noncontrolling Interests	$-784,955,000	$-589,526,000	$-526,244,000	$-388,955,000
Net Income Continuous Operations	$-784,955,000	$-589,526,000	$-526,244,000	$-388,955,000
Pretax Income	$-784,955,000	$-589,526,000	$-526,244,000	$-388,955,000
Special Income Charges	$-121,249,000	$0	$0	$-24,939,000
Interest Income Non Operating	$48,420,000	$51,534,000	$27,629,000	$11,342,000
Operating Income	$-612,258,000	$-536,248,000	$-496,205,000	$-324,202,000
Gross Profit	$-327,987,000	$-320,934,000	$-322,593,000	$-146,225,000
Per Share
Diluted EPS	$-6.54	$-5.26	$-5.45	$-4.33
Basic EPS	$-6.54	$-5.26	$-5.45	$-4.33
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-553,913,000	$-494,783,000	$-456,684,000	$-307,046,000
Total Unusual Items	$-117,049,000	$1,300,000	$0	$-24,939,000
Total Unusual Items Excluding Goodwill	$-117,049,000	$1,300,000	$0	$-24,939,000
Reconciled Depreciation	$10,125,000	$9,531,000	$11,892,000	$5,814,000
EBITDA (Bullshit earnings)	$-670,962,000	$-493,483,000	$-456,684,000	$-331,985,000
EBIT	$-681,087,000	$-503,014,000	$-468,576,000	$-337,799,000
Diluted Average Shares	$120,103,000	$111,979,000	$96,524,000	$89,825,000
Basic Average Shares	$120,103,000	$111,979,000	$96,524,000	$89,825,000
Diluted NI Availto Com Stockholders	$-784,955,000	$-589,526,000	$-526,244,000	$-388,955,000
Other Special Charges	$121,249,000	-	-	$24,939,000
Gain On Sale Of Security	$4,200,000	$1,300,000	-	-
Research And Development	$416,026,000	$339,408,000	$330,123,000	$240,813,000
Selling General And Administration	$284,271,000	$215,314,000	$173,612,000	$177,977,000
Other Gand A	$284,271,000	$215,314,000	$173,612,000	$177,977,000

Fetched: 2026-07-16

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$-659,625,000	$-135,372,000	$-386,323,000	$-107,900,000
Total Assets	$1,424,537,000	$1,401,673,000	$824,316,000	$1,014,775,000
Total Non Current Assets	$507,562,000	$293,733,000	$196,265,000	$219,589,000
Other Non Current Assets	$17,341,000	$7,705,000	$7,996,000	$9,691,000
Investmentin Financial Assets	$335,048,000	$145,055,000	$40,534,000	$46,708,000
Current Assets	$916,975,000	$1,107,940,000	$628,051,000	$795,186,000
Other Current Assets	$16,990,000	$15,276,000	$11,944,000	$12,462,000
Receivables	$17,764,000	$16,650,000	$1,283,000	$147,000
Accounts Receivable	$17,764,000	$16,650,000	$1,283,000	$147,000
Cash Cash Equivalents And Short Term Investments	$882,221,000	$1,076,014,000	$614,824,000	$782,577,000
Cash And Cash Equivalents	$122,518,000	$94,857,000	$113,024,000	$65,582,000
Prepaid Assets	-	-	-	-
Debt
Net Debt	$1,034,644,000	$562,260,000	$504,429,000	$544,994,000
Total Debt	$1,284,243,000	$788,677,000	$755,771,000	$750,300,000
Long Term Debt And Capital Lease Obligation	$1,223,951,000	$758,179,000	$727,800,000	$736,513,000
Long Term Debt	$1,115,981,000	$645,597,000	$607,373,000	$609,618,000
Current Debt And Capital Lease Obligation	$60,292,000	$30,498,000	$27,971,000	$13,787,000
Current Debt	$41,181,000	$11,520,000	$10,080,000	$958,000
Other Current Borrowings	$41,181,000	$11,520,000	$10,080,000	$958,000
Liabilities
Total Liabilities Net Minority Interest	$2,084,162,000	$1,537,045,000	$1,210,639,000	$1,122,675,000
Total Non Current Liabilities Net Minority Interest	$1,881,710,000	$1,357,371,000	$1,107,961,000	$1,038,058,000
Other Non Current Liabilities	$657,759,000	$599,192,000	$380,161,000	$301,545,000
Current Liabilities	$202,452,000	$179,674,000	$102,678,000	$84,617,000
Other Current Liabilities	$34,933,000	$21,114,000	$10,559,000	$1,123,000
Current Deferred Liabilities	$1,612,000	$52,370,000	$0	-
Payables And Accrued Expenses	$60,465,000	$40,560,000	$34,893,000	$47,940,000
Payables	$22,337,000	$20,369,000	$21,507,000	$25,611,000
Accounts Payable	$22,337,000	$20,369,000	$21,507,000	$25,611,000
Non Current Deferred Liabilities	-	-	-	$0
Equity
Common Stock Equity	$-659,625,000	$-135,372,000	$-386,323,000	$-107,900,000
Total Equity Gross Minority Interest	$-659,625,000	$-135,372,000	$-386,323,000	$-107,900,000
Stockholders Equity	$-659,625,000	$-135,372,000	$-386,323,000	$-107,900,000
Gains Losses Not Affecting Retained Earnings	$630,000	$2,398,000	$-10,000	$-3,590,000
Other Equity Adjustments	$630,000	$2,398,000	$-10,000	$-3,590,000
Retained Earnings	$-3,486,719,000	$-2,701,764,000	$-2,112,238,000	$-1,585,994,000
Other
Ordinary Shares Number	$122,943,172	$118,209,139	$101,637,922	$94,833,975
Share Issued	$122,943,172	$118,209,139	$101,637,922	$94,833,975
Tangible Book Value	$-659,625,000	$-135,372,000	$-386,323,000	$-107,900,000
Invested Capital	$497,537,000	$521,745,000	$231,130,000	$502,676,000
Working Capital	$714,523,000	$928,266,000	$525,373,000	$710,569,000
Capital Lease Obligations	$127,081,000	$131,560,000	$138,318,000	$139,724,000
Total Capitalization	$456,356,000	$510,225,000	$221,050,000	$501,718,000
Additional Paid In Capital	$2,826,341,000	$2,563,876,000	$1,725,823,000	$1,481,590,000
Capital Stock	$123,000	$118,000	$102,000	$94,000
Common Stock	$123,000	$118,000	$102,000	$94,000
Preferred Stock	$0	$0	$0	$0
Long Term Capital Lease Obligation	$107,970,000	$112,582,000	$120,427,000	$126,895,000
Current Deferred Revenue	$1,612,000	$52,370,000	$0	-
Current Capital Lease Obligation	$19,111,000	$18,978,000	$17,891,000	$12,829,000
Pensionand Other Post Retirement Benefit Plans Current	$45,150,000	$35,132,000	$29,255,000	$21,767,000
Current Accrued Expenses	$38,128,000	$20,191,000	$13,386,000	$22,329,000
Investments And Advances	$335,048,000	$145,055,000	$40,534,000	$46,708,000
Available For Sale Securities	$335,048,000	$145,055,000	$40,534,000	$46,708,000
Net PPE	$155,173,000	$140,973,000	$147,735,000	$163,190,000
Accumulated Depreciation	$-47,301,000	$-37,177,000	$-28,348,000	$-17,094,000
Gross PPE	$202,474,000	$178,150,000	$176,083,000	$180,284,000
Leases	$80,203,000	$66,874,000	$66,874,000	$65,912,000
Construction In Progress	$10,351,000	$4,067,000	$220,000	$741,000
Other Properties	$99,938,000	$97,787,000	$99,665,000	$103,675,000
Machinery Furniture Equipment	$11,982,000	$9,422,000	$9,324,000	$9,956,000
Properties	$0	$0	$0	$0
Other Short Term Investments	$759,703,000	$981,157,000	$501,800,000	$716,995,000
Non Current Deferred Revenue	-	-	-	$0

Fetched: 2026-07-16

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-534,816,000	$-399,796,000	$-415,749,000	$-310,851,000
Operating Activities
Operating Cash Flow	$-510,009,000	$-395,890,000	$-414,333,000	$-299,516,000
Cash Flow From Continuing Operating Activities	$-510,009,000	$-395,890,000	$-414,333,000	$-299,516,000
Operating Gains Losses	$-4,225,000	$-1,274,000	$35,000	$2,800,000
Investing Activities
Capital Expenditure	$-24,807,000	$-3,906,000	$-1,416,000	$-11,335,000
Investing Cash Flow	$16,666,000	$-553,097,000	$239,253,000	$-262,134,000
Cash Flow From Continuing Investing Activities	$16,666,000	$-553,097,000	$239,253,000	$-262,134,000
Financing Activities
Issuance Of Capital Stock	$0	$706,844,000	$164,233,000	$0
Financing Cash Flow	$524,458,000	$930,611,000	$221,317,000	$516,166,000
Cash Flow From Continuing Financing Activities	$524,458,000	$930,611,000	$221,317,000	$516,166,000
Net Other Financing Charges	$172,532,000	$180,369,000	$39,483,000	$163,962,000
Net Common Stock Issuance	$0	$706,844,000	$164,233,000	$0
Common Stock Issuance	$0	$706,844,000	$164,233,000	$0
Other
Repayment Of Debt	$-413,513,000	$-9,618,000	$-858,000	$-188,925,000
Issuance Of Debt	$729,460,000	$0	$0	$523,586,000
Interest Paid Supplemental Data	$22,914,000	$25,970,000	$10,295,000	$15,165,000
End Cash Position	$125,632,000	$95,232,000	$113,399,000	$67,182,000
Beginning Cash Position	$95,232,000	$113,399,000	$67,182,000	$112,666,000
Effect Of Exchange Rate Changes	$-715,000	$209,000	$-20,000	$0
Changes In Cash	$31,115,000	$-18,376,000	$46,237,000	$-45,484,000
Proceeds From Stock Option Exercised	$35,979,000	$53,016,000	$18,459,000	$17,543,000
Net Issuance Payments Of Debt	$315,947,000	$-9,618,000	$-858,000	$334,661,000
Net Long Term Debt Issuance	$315,947,000	$-9,618,000	$-858,000	$334,661,000
Long Term Debt Payments	$-413,513,000	$-9,618,000	$-858,000	$-188,925,000
Long Term Debt Issuance	$729,460,000	$0	$0	$523,586,000
Net Investment Purchase And Sale	$41,473,000	$-549,191,000	$240,669,000	$-250,799,000
Sale Of Investment	$1,109,646,000	$744,225,000	$875,880,000	$604,594,000
Purchase Of Investment	$-1,068,173,000	$-1,293,416,000	$-635,211,000	$-855,393,000
Net PPE Purchase And Sale	$-24,807,000	$-3,906,000	$-1,416,000	$-11,335,000
Purchase Of PPE	$-24,807,000	$-3,906,000	$-1,416,000	$-11,335,000
Change In Working Capital	$-35,628,000	$35,664,000	$3,089,000	$-24,704,000
Change In Other Working Capital	$-50,758,000	$52,370,000	-	$-87,000,000
Change In Other Current Liabilities	$-17,089,000	$-8,600,000	$-10,991,000	$-2,330,000
Change In Payables And Accrued Expense	$36,266,000	$9,699,000	$13,620,000	$15,368,000
Change In Accrued Expense	$33,603,000	$14,182,000	$17,103,000	$10,844,000
Change In Payable	$2,663,000	$-4,483,000	$-3,483,000	$4,524,000
Change In Account Payable	$2,663,000	$-4,483,000	$-3,483,000	$4,524,000
Change In Prepaid Assets	$-2,933,000	$-2,438,000	$1,596,000	$-7,414,000
Change In Receivables	$-1,114,000	$-15,367,000	$-1,136,000	$56,672,000
Changes In Account Receivables	$-1,114,000	$-15,367,000	$-1,136,000	$56,672,000
Other Non Cash Items	$192,388,000	$51,875,000	$24,830,000	$57,676,000
Stock Based Compensation	$112,286,000	$97,840,000	$72,065,000	$47,853,000
Depreciation Amortization Depletion	$10,125,000	$9,531,000	$11,892,000	$5,814,000
Depreciation And Amortization	$10,125,000	$9,531,000	$11,892,000	$5,814,000
Depreciation	$10,125,000	$9,531,000	$11,892,000	$5,814,000
Gain Loss On Investment Securities	$-4,225,000	$-1,319,000	$35,000	$107,000
Gain Loss On Sale Of PPE	$0	$45,000	$0	$0
Net Income From Continuing Operations	$-784,955,000	$-589,526,000	$-526,244,000	$-388,955,000
Asset Impairment Charge	-	-	$0	$0

Fetched: 2026-07-16